Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Viracta Therapeutics (VIRX) has issued an announcement.
Michael Faerm has been appointed as the new Chief Financial Officer of Viracta Therapeutics, Inc., effective May 13, 2024. Alongside his role as CFO, he will act as the principal financial and accounting officer. Faerm brings extensive experience from his previous roles in biopharmaceutical companies and his academic credentials, including an MBA from Harvard. His compensation includes a base salary of $480,000, a potential 40% bonus, and stock options that vest over time, with additional incentives if the company achieves certain financial milestones. The appointment and compensation terms are part of a strategic move to enhance Viracta Therapeutics’ executive team.
For a thorough assessment of VIRX stock, go to TipRanks’ Stock Analysis page.
